 |
Robert A. Lepley, Ph.D.
Robert Lepley joined TIS Group during
the fall 2000 as a Research Strategist.
Bob was previously employed as a research
scientist in the pharmaceutical industry
and as a university faculty member. Bob
has published his scientific work in
peer reviewed, high impact scientific
journals such as the Journal of Biological
Chemistry and the Journal of Clinical
Investigation as well book chapters. With
more than 20-years of professional experience
in biomedical research, Bob is thoroughly familiar
with the biomedical research and development
landscape for drugs, medical devices and
diagnostics encompassing preclinical
research, the FDA clinical trial process and
intellectual property considerations. At TIS
Group, Bob's principle areas of research focus
are biopharmaceutics and health care, energy
(hydrocarbon and alternative), country specific
macro analyses (natural resources group and Asia)
and geostrategic analyses (emerging market focus).
Bob regularly contributes thematic topics and in
depth articles to the monthly TIS Group
Institutional Strategist U.S. Market edition
monograph (the "Red Book"), the Instrutional
Strategist Global Markets edition (the"Blue
Book") and the daily Market Intelligence
Report. (the "MIR").
Education
- Ph.D. - University of Minnesota;
1983
- B.S. - University of Minnesota; 1974
Professional Experience
-
Parke-Davis Pharmaceutical Research
– Senior Research Associate
-
University of Colorado health
Sciences Center – Assistant
Professor, Department of
Pharmacology (primary appointment) /
Pulmonary Sciences and Critical Care
Medicine (secondary appointment)
Upjohn Pharmaceuticals – Senior
Research Scientist
-
University of Minnesota – Research
Laboratory Technician
Affiliations/Memberships
Andrew Roalstad, MBA.
Mr. Roalstad is Portfolio Manager,
Analyst, and Head Trader at TIS Group.
Andrew has appreciable experience in
trading a wide range of investment
vehicles, including domestic and
international equities & bonds, both
long and short, currencies,
ETFs
options, futures contracts and emerging
market securities. He manages three
portfolios, including a U.S. Small-Cap
Equity strategy, a U.S. Equity strategy,
and a pure Exchange-Traded Fund product,
called the
Splitrock
Investment Strategies. His
expertise and proprietary trading
techniques have enabled him to
consistently outperform his portfolio
benchmarks. His monthly-published
“Investment Theme” research, backed by
solid quantitative and fundamental
analysis, generates profitable synergies
for the firm’s managed accounts.
Andrew has been involved in the
investment management industry since
1994.
St.
Olaf
College, B.A., University of St. Thomas,
M.B.A.
His work has been noted and used in
various publications such as
Barron’s,
Bloomberg News,
TheStreet.com,
Morning
Call on Bloomberg TV, and
German finance magazine,
Finanzen
€uro.
|
